APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers. Academic Article uri icon

Overview

MeSH

  • Animals
  • DNA Mutational Analysis
  • Exons
  • GTP-Binding Proteins
  • Humans
  • Male
  • Mice
  • Signal Transduction
  • Tumor Cells, Cultured
  • beta Catenin
  • beta-Transducin Repeat-Containing Proteins

MeSH Major

  • Cytoskeletal Proteins
  • Genes, APC
  • Mutation
  • Prostatic Neoplasms
  • Trans-Activators

abstract

  • Genetic alterations serve as beacons for the involvement of specific pathways in tumorigenesis. It was previously shown that 5% of prostate tumors harbor CTNNB1 mutations, suggesting that this tumor type may involve a deregulated APC/CTNNB1 pathway. To explore this possibility further, we searched for mutations in genes implicated in this pathway in 22 samples that included cell lines, xenografts, and primary tumors. We identified seven alterations: two in CTNNB1, three in APC, and two in hTRCP1 (also known as BTRC) which controls the degradation of CTNNB1. Alterations in the CTNNB1 regulatory domain, APC, and hTRCP1 were mutually exclusive, consistent with their equivalent effects on CTNNB1 stability. These results suggest that CTNNB1 signaling plays a critical role in the development of a significant fraction of prostate cancers. Moreover, they provide the first evidence that hTRCP1 plays a role in human neoplasia. Copyright 2002 Wiley-Liss, Inc.

publication date

  • May 2002

has subject area

  • Animals
  • Cytoskeletal Proteins
  • DNA Mutational Analysis
  • Exons
  • GTP-Binding Proteins
  • Genes, APC
  • Humans
  • Male
  • Mice
  • Mutation
  • Prostatic Neoplasms
  • Signal Transduction
  • Trans-Activators
  • Tumor Cells, Cultured
  • beta Catenin
  • beta-Transducin Repeat-Containing Proteins

Research

keywords

  • Journal Article

Identity

Language

  • eng

PubMed ID

  • 11921277

Additional Document Info

start page

  • 9

end page

  • 16

volume

  • 34

number

  • 1